Acelyrin Inc. (NASDAQ:SLRN) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET

Company Participants

Tyler Marciniak - Vice President, Investor Relations, Communications, Corporate Operations

Shao-Lee Lin - Founder, Chief Executive Officer and Director

Gil Labrucherie - Chief Financial Officer

Conference Call Participants

Yasmeen Rahimi - Analyst, Piper Sandler

Emily Bodnar - Analyst, H.C. Wainwright and Company

Akash Tewari - Analyst, Jefferies

Tyler Van Buren - TD Cowen

Vikram Purohit - Morgan Stanley

Operator

Good day, and thank you for standing by. Welcome to the Acelyrin Q3 2023 Earnings Conference Call. [Operator Instructions].

I would now like to hand the conference over to Tyler Marciniak, Vice President of Investor Relations, Communications, and Corporate Operations. Please go ahead.

Tyler Marciniak

Thank you, operator. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind the audience that this conference call will contain forward-looking statements, such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results and investments, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially.

We urge you to review the risk factors section of our form 10-Q for the quarter ended June 30, 2023 filed with the SEC and also available on our website at acelyrin.com along with statements in today's press release and our slide presentation, which identifies certain factors that could cause our actual results, performance, and events to differ materially. Additionally, these statements are based on information available to us today, November 7, 2023, and we undertake no obligation to update them as circumstances may change.

Joining us on today's call are Dr. Shao-Lee Lin, our founder and CEO; and Gil Labrucherie, our chief financial officer. I will now turn the call over to Dr. Lin. Shao-Lee?

Shao-Lee Lin

Thank you, Tyler. Good afternoon, everyone. Thank you for joining us for Acelyrin Third Quarter Update Call. As we approach the end of 2023, we feel fortunate for the progress we have made throughout the course of the year. We began in January with the transformative expansion of our portfolio through the acquisition of another private INI company. And in May, we were pleased to close the successful IPO in a challenging market environment. We are grateful to our investors for walking alongside with us in our journey as we remain focused on building a leading INI company and continuing to advance programs across multiple autoimmune and inflammatory diseases with the goal to deliver transformative medicines for patients.